이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Viridian Therapeutics 관리

관리 기준 확인 1/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Steve Mahoney

최고 경영자

US$13.0m

총 보상

CEO 급여 비율	0.9%
CEO 임기	less than a year
CEO 소유권	n/a
경영진 평균 재임 기간	less than a year
이사회 평균 재임 기간	3.7yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Steve Mahoney 의 보수는 Viridian Therapeutics 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2024	n/a	n/a	-US$218m
Dec 31 2023	US$13m	US$113k	-US$238m

보상 대 시장: Steve 의 총 보상 ($USD 13.02M )은 German 시장( $USD 1.31M ).

보상과 수익: Steve 의 보상을 회사 성과와 비교하기에는 데이터가 부족합니다.

CEO

Steve Mahoney (53 yo)

less than a year

테뉴어

US$13,022,654

보상

Mr. Stephen F. Mahoney, also known as Steve, J. D. serves as President, CEO & Director at Viridian Therapeutics, Inc. since October 30, 2023. He served as President, Chief Financial and Operating Officer a...

리더십 팀

이름	위치	테뉴어	보상	소유권
Stephen Mahoney	CEO, President & Director	less than a year	US$13.02m	데이터 없음
Seth Harmon	Senior VP of Finance and Accounting	less than a year	US$6.67m	0.0016% $ 12.2k
Thomas Beetham	Chief Operating Officer	less than a year	US$5.17m	데이터 없음
Eric Olson	Co-Founder & Chairman of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Michael Bristow	Co-Founder & Member of the Scientific Advisory Board	no data	데이터 없음	데이터 없음
Marvin Caruthers	Co-Founder & Scientific Advisory Board Member	no data	데이터 없음	데이터 없음
Vahe Bedian	Co-Founder & Scientific Advisor	no data	데이터 없음	데이터 없음
Jennifer Tousignant	Chief Legal Officer	less than a year	데이터 없음	데이터 없음
John Jordan	Vice President of Investor Relations & Corporate Communications	no data	데이터 없음	데이터 없음
Anthony Casciano	Chief Commercial Officer	1.2yrs	데이터 없음	데이터 없음
Thomas Ciulla	Chief Medical Officer	1.4yrs	데이터 없음	0.0012% $ 9.2k
Shan Wu	Chief Business Officer	less than a year	데이터 없음	데이터 없음

0.7yrs

평균 재임 기간

53.5yo

평균 연령

경험이 풍부한 관리: 1S1 의 관리팀은 경험 (평균 재직 기간 0.7 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Stephen Mahoney	CEO, President & Director	less than a year	US$13.02m	데이터 없음
Eric Olson	Co-Founder & Chairman of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Michael Bristow	Co-Founder & Member of the Scientific Advisory Board	no data	데이터 없음	데이터 없음
Marvin Caruthers	Co-Founder & Scientific Advisory Board Member	no data	데이터 없음	데이터 없음
Arlene Morris	Independent Director	6.4yrs	US$477.83k	0% $ 0
Victor Ambros	Scientific Advisory Board Member	no data	데이터 없음	데이터 없음
Stefanie Dimmeler	Scientific Advisory Board Member	no data	데이터 없음	데이터 없음
Jeffery Molkentin	Scientific Advisory Board Member	no data	데이터 없음	데이터 없음
Eva van Rooij	Scientific Advisory Board Member	no data	데이터 없음	데이터 없음
Tomas Kiselak	Independent Chairperson of Board	3.7yrs	US$503.83k	0% $ 0
Jennifer Moses	Independent Director	2.9yrs	US$467.83k	0% $ 0
Peter Harwin	Independent Director	3.7yrs	US$471.83k	0% $ 0

3.7yrs

평균 재임 기간

53yo

평균 연령

경험이 풍부한 이사회: 1S1 의 이사회는 경험(평균 재직 기간 3.7 년)으로 간주됩니다.

Viridian Therapeutics 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

Viridian Therapeutics, Inc., Annual General Meeting, Jun 17, 2024

Viridian Therapeutics, Inc. Appoints Jennifer Tousignant as Chief Legal Officer

Viridian Therapeutics, Inc. Announces Executive Changes

Viridian Therapeutics, Inc. Announces the Resignation of Scott Myers as a Member of the Board of Directors

Viridian Therapeutics, Inc. Appoints Sarah Gheuens to its Board of Directors

Viridian Therapeutics, Inc. Announces Executive Changes

Recent updates

First quarter 2024 earnings released: US$0.79 loss per share (vs US$1.61 loss in 1Q 2023)

Viridian Therapeutics, Inc., Annual General Meeting, Jun 17, 2024

New major risk - Shareholder dilution

Full year 2023 earnings released: US$5.31 loss per share (vs US$4.05 loss in FY 2022)

Viridian Therapeutics, Inc. Appoints Jennifer Tousignant as Chief Legal Officer

Viridian Therapeutics, Inc. has filed a Follow-on Equity Offering.

Viridian Therapeutics, Inc. Announces Executive Changes

Third quarter 2023 earnings released: US$1.09 loss per share (vs US$0.86 loss in 3Q 2022)

Viridian Therapeutics, Inc. announced that it has received $185.000072 million in funding from a group of investors

Viridian Therapeutics, Inc. Announces the Resignation of Scott Myers as a Member of the Board of Directors

Viridian Therapeutics, Inc. announced that it expects to receive $185.000072 million in funding from a group of investors

Viridian Therapeutics, Inc. Appoints Sarah Gheuens to its Board of Directors

Viridian Therapeutics, Inc. Announces Executive Changes

Second quarter 2023 earnings released: US$1.27 loss per share (vs US$1.06 loss in 2Q 2022)

Viridian Therapeutics, Inc. Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)

Viridian Therapeutics, Inc. Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)

First quarter 2023 earnings released: US$1.61 loss per share (vs US$0.98 loss in 1Q 2022)

President recently bought €92k worth of stock

President recently bought €149k worth of stock

Full year 2022 earnings released: US$4.05 loss per share (vs US$6.66 loss in FY 2021)

High number of new and inexperienced directors

Viridian Therapeutics, Inc. Appoints Scott Myers as Chief Executive Officer

Viridian Therapeutics, Inc. Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating Low Dose VRDN-001 in Patients with Thyroid Eye Disease (Ted)

Viridian Therapeutics Announces First Patient Enrolled in the ‘Thrive’ Phase 3 Trial in Patients with Thyroid Eye Disease

High number of new and inexperienced directors

Viridian Therapeutics, Inc Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Thyroid Eye Disease (TED)

Viridian Therapeutics, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Viridian Therapeutics, Inc. Presents Positive Clinical Data from Ongoing VRDN-001 Phase 1/2 Trial in Active Thyroid Eye Disease (TED) Patients During Late-Breaking Presentations at the American Thyroid Association (ATA) 91st Annual Meeting

Second quarter 2022 earnings released: US$1.06 loss per share (vs US$2.22 loss in 2Q 2021)

Viridian Therapeutics, Inc. Announces Positive Initial Clinical Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Thyroid Eye Disease (TED)

Viridian Therapeutics, Inc. to Report Q2, 2022 Results on Aug 15, 2022

Viridian Therapeutics Appoints Carrie Melvin as Chief Operating Officer

First quarter 2022 earnings released: US$0.98 loss per share (vs US$2.91 loss in 1Q 2021)

Viridian Therapeutics, Inc. to Report Q1, 2022 Results on May 12, 2022

High number of new and inexperienced directors

Viridian Therapeutics, Inc. announced that it expects to receive $75 million in funding from Hercules Capital, Inc.

Viridian Therapeutics, Inc. to Report Q4, 2021 Results on Mar 10, 2022

Viridian Therapeutics Announces FDA Clearance of Investigational New Drug Application to Initiate Clinical Development of VRDN-002

Viridian Therapeutics Submits Investigational New Drug Application for VRDN-002 to the U.S. Food and Drug Administration

Viridian Therapeutics Announces First Subject Dosed in Phase 1/2 Clinical Trial of VRDN-001 for Thyroid Eye Disease (TED)

High number of new and inexperienced directors

Second quarter 2021 earnings released: US$2.22 loss per share (vs US$1.82 loss in 2Q 2020)

Independent Director Joseph Turner has left the company

Independent Chairman of the Board Jeffrey Hatfield has left the company

CFO, Secretary & Treasurer has left the company

First quarter 2021 earnings released: US$2.91 loss per share (vs US$2.65 loss in 1Q 2020)

Full year 2020 earnings released: US$31.13 loss per share (vs US$20.04 loss in FY 2019)

New 90-day low: €12.68

Viridian Therapeutics, Inc. Appoints Jonathan Violin, as Chief Executive Officer

miRagen Therapeutics, Inc. Announces Executive Changes

New 90-day high: €18.14

Miragen Therapeutics, Inc. Enters into License Agreement with Xencor for Use of Xtend™ Antibody Technology for Investigational Antibodies to Treat Thyroid Eye Disease

Miragen Therapeutics, Inc. Announces Diana Escolar, M.D. to Resign as the Chief Medical Officer of the Company, Effective as of January 1, 2021

Revenue misses expectations

New 90-day high: €1.04

Miragen Therapeutics, Inc. (NasdaqCM:MGEN) acquired Viridian Therapeutics, Inc. for approximately $110 million.

Miragen Therapeutics, Inc. Announces Management Changes

Miragen Receives A Letter from the Listing Qualifications Department of the Nasdaq Stock Market

New 90-day low: €0.38

miRagen Therapeutics, Inc. Announces Internal Review of Preliminary Topline Data for the Phase 2 SOLAR Clinical Trial of Cobomarsen in Patients with Cutaneous T-Cell Lymphoma

New 90-day low: €0.69

Miragen Therapeutics, Inc. Conducts Comprehensive Review of Its Research and Development Pipeline

miRagen Therapeutics, Inc. Announces Leadership Transition

New 90-day low - €0.72

New 90-day high - €1.18

Miragen Therapeutics to Report Q2, 2020 Results on Aug 05, 2020

Miragen Therapeutics(NasdaqCM:MGEN) dropped from Russell Microcap Value Index

CEO 보상 분석

CEO